Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Germany's Institute for Quality and Efficiency in Health Care (IQWiG) said in a preliminary benefit assessment that Xalkori crizotinib
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury